Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

April 13, 2023 at 08:00 AM EDT

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

More News

3 Big Earnings Misses: Is It Time to Buy the Dip?

November 09, 2025

Via MarketBeat

Is Robinhood's 11% Post-Earnings Fall a Buy-the-Dip Opportunity?

November 09, 2025

Via MarketBeat

AI Demand Is Coming—Is Microchip Technology Ready?

November 09, 2025

Via MarketBeat

Why Investors Have Flocked to 2 Unorthodox ETFs This Month

November 09, 2025

Via MarketBeat

Rivian’s Chart Says Go, But Some Analysts Still Say No

November 08, 2025

Via MarketBeat

Recent Quotes

Symbol	Price	Change (%)
AMZN	244.41	+1.37 (0.56%)
AAPL	268.47	-1.30 (-0.48%)
AMD	233.54	-4.16 (-1.75%)
BAC	53.20	-0.09 (-0.17%)
GOOG	279.70	-5.64 (-1.98%)
META	621.71	+2.77 (0.45%)
MSFT	496.82	-0.28 (-0.06%)
NVDA	188.15	+0.07 (0.04%)
ORCL	239.26	-4.54 (-1.86%)
TSLA	429.52	-16.39 (-3.68%)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.